219 related articles for article (PubMed ID: 28096720)
1. Update on Gastrointestinal Stromal Tumors for Radiologists.
Tirumani SH; Baheti AD; Tirumani H; O'Neill A; Jagannathan JP
Korean J Radiol; 2017; 18(1):84-93. PubMed ID: 28096720
[TBL] [Abstract][Full Text] [Related]
2. Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis.
Zhi X; Zhou X; Wang W; Xu Z
PLoS One; 2013; 8(11):e79275. PubMed ID: 24223922
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
Dong Z; Gao J; Gong J; Li J; Li Y; Wang X; Li Y; Shen L; Li J
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1286-1289. PubMed ID: 27928801
[TBL] [Abstract][Full Text] [Related]
4. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
5. Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients.
Yoon S; Ryu MH; Yoo C; Beck MY; Ryoo BY; Kang YK
J Korean Med Sci; 2013 Aug; 28(8):1248-52. PubMed ID: 23960456
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
[TBL] [Abstract][Full Text] [Related]
7. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
8. Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.
Ihle MA; Huss S; Jeske W; Hartmann W; Merkelbach-Bruse S; Schildhaus HU; Büttner R; Sihto H; Sundby Hall K; Eriksson M; Reichardt P; Joensuu H; Wardelmann E
PLoS One; 2018; 13(2):e0193048. PubMed ID: 29451912
[TBL] [Abstract][Full Text] [Related]
9. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
Heinrich MC; Rankin C; Blanke CD; Demetri GD; Borden EC; Ryan CW; von Mehren M; Blackstein ME; Priebat DA; Tap WD; Maki RG; Corless CL; Fletcher JA; Owzar K; Crowley JJ; Benjamin RS; Baker LH
JAMA Oncol; 2017 Jul; 3(7):944-952. PubMed ID: 28196207
[TBL] [Abstract][Full Text] [Related]
10. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
11. CT scan is not everything in the evaluation of a patient with gastrointestinal tumors (GIST) under imatinib therapy.
Wang CM; Fu H; Zhao GF; Wang J; Shi YQ
Pathol Oncol Res; 2012 Oct; 18(4):1095-7. PubMed ID: 21927980
[No Abstract] [Full Text] [Related]
12. Combined Therapy of Gastrointestinal Stromal Tumors.
Rutkowski P; Hompes D
Surg Oncol Clin N Am; 2016 Oct; 25(4):735-59. PubMed ID: 27591496
[TBL] [Abstract][Full Text] [Related]
13. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
Gao J; Tian Y; Li J; Sun N; Yuan J; Shen L
Med Oncol; 2013 Jun; 30(2):522. PubMed ID: 23456621
[TBL] [Abstract][Full Text] [Related]
14. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
Van den Abbeele AD; Gatsonis C; de Vries DJ; Melenevsky Y; Szot-Barnes A; Yap JT; Godwin AK; Rink L; Huang M; Blevins M; Sicks J; Eisenberg B; Siegel BA
J Nucl Med; 2012 Apr; 53(4):567-74. PubMed ID: 22381410
[TBL] [Abstract][Full Text] [Related]
15. Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy.
Pandey R; Kochar R
J Gastrointest Cancer; 2012 Dec; 43(4):547-52. PubMed ID: 22847491
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal stromal tumors: who should get imatinib and for how long?
Balachandran VP; DeMatteo RP
Adv Surg; 2014; 48(1):165-83. PubMed ID: 25293614
[TBL] [Abstract][Full Text] [Related]
17. Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection.
Tirumani SH; Shinagare AB; Jagannathan JP; Krajewski KM; Ramaiya NH; Raut CP
Eur J Surg Oncol; 2014 Apr; 40(4):420-8. PubMed ID: 24238762
[TBL] [Abstract][Full Text] [Related]
18. Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503.
Liu NN; Ohkouchi M; Hashikura Y; Kajimoto N; Matsuda I; Isozaki K; Toh Y; Takahashi T; Nishida T; Hirota S
Lab Invest; 2013 May; 93(5):502-7. PubMed ID: 23459373
[TBL] [Abstract][Full Text] [Related]
19. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH
Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
[TBL] [Abstract][Full Text] [Related]
20. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]